

REVIEW ARTICLE

Advancements in Novel Drug Delivery Systems: A Comprehensive Review

Aashima Parashar¹, Abhishek Gautam², Shilpi Sachdeva^{3*}, Anu Sharma¹, Sandeep Kumar^{1*}

1. ASBASJSM College of Pharmacy, Bela Ropar (Punjab)

2. Idma Laboratories Limited, Panchkula (Haryana)

3. Sachdeva College of Pharmacy, Gharuan (Punjab)

*Corresponding author's email: drsandeeprajapura@gmail.com shilpimsachdeva@gmail.com

ABSTRACT

Recent developments in new drug delivery systems aim to improve patient outcomes and therapeutic efficacy. Traditional drug delivery methods often face challenges such as poor bioavailability and systemic toxicity. Novel approaches, including liposome, nanoparticles, micelles, transdermal drug delivery system, offer promising solutions to overcome these limitations. The review discusses challenges, future prospects and applications of these systems in targeted and controlled drug delivery. Overall, this review provides a concise overview of innovative drug delivery strategies, offering insights for researchers and clinicians to advance the field and meet evolving healthcare needs.

Keywords: Liposomes, Polymeric micelles, Nanoparticles, Implantable Drug Delivery System, Transdermal Drug Delivery, Gene Delivery System

Received 24.03.2025

Revised 20.04.2025

Accepted 24.05.2025

How to cite this article:

Aashima P, Abhishek G, Shilpi S, Anu S, Sandeep K. Advancements in Novel Drug Delivery Systems: A Comprehensive Review. Adv. Biores., Vol 16 (3) May 2025: 389-400.

INTRODUCTION

Drug Delivery System (DDS) comprises a technological system which is responsible for formulation and storage of drug molecule in a suitable form such as solution or tablet providing ease of administration [1,2]. The routes from which drugs can be administered are not limited to oral only [3,4], sublingual and buccal are other routes used for administration [5], ophthalmic and nasal [6,7], subcutaneous and transdermal [8,9], transvaginal and anal [10,11] and intravesical [12,13].

There is a recent development in drug delivery system by the utilization of updated systems for more controlled, convenient as well as targeted delivery. Every DDS possess its own speciality that decides its mechanism and release rate. This is mainly due to the variations in chemical, morphological and physical properties that decides their affinities towards various drug substances [14]. The development of new drug delivery system completely depends on promotion of therapeutic effects of API and minimization of their toxic effects by elevating persistence and amount of API in the proximity of target cell and decreasing the exposure of drug to non-target cells [15,16].

NDDS is composed of those based on physical and biochemical mechanisms. Physical mechanisms are also known as controlled drug delivery systems that include diffusion, osmosis, erosion, electro transport, and dissolution. Biochemical mechanism is composed of monoclonal antibodies, vector system and gene therapy, liposomes and polymer drug adducts. Therapeutic benefits of various new drug delivery system is composed of optimization of action duration of drug, decreasing their dosage frequency, regulating the release site and maintenance of constant drug levels [17,18,19].

The field of medicine has witnessed various advancements over the years, which leads to improvement in patient outcomes and enhancement in quality of life. Among these advancements, the development of novel drug delivery systems stands out as a pioneering endeavor that has transformed the way we administer medications. These innovative systems offer targeted delivery, improved efficacy, reduced side effects, and enhanced patient compliance, marking a significant paradigm shift in pharmaceutical science.

UNDERSTANDING DRUG DELIVERY SYSTEMS

Drug delivery systems refer to technologies and approaches that are designed for the transportation of therapeutic agents to specific target sites within the body. Traditional drug delivery methods often suffer from limitations such as non-specific distribution, poor bioavailability, and rapid clearance from the body. Novel drug delivery systems address these challenges by providing controlled release, targeted delivery, and improved pharmacokinetics.

Types of Novel Drug Delivery Systems

- ✓ **Nanotechnology-Based Delivery Systems:** Nanotechnology has revolutionized drug delivery by enabling of precise manipulation of drug particles at the nanoscale. Nano-carriers such as nanoparticles, liposomes and dendrimers offer advantages such as prolonged circulation time, enhanced cellular uptake, and targeted delivery to diseased tissues [20].
- ✓ **Polymeric Micelles:** Polymeric micelles are defined as self-assembling nanostructures which are composed of amphiphilic block copolymers. These micelles can encapsulate hydrophobic drugs within their core, while the hydrophilic shell provides the biocompatibility and stability. Polymeric micelles offer improved solubility, targeted delivery and controlled release to specific tissues [21].
- ✓ **Implantable Drug Delivery Systems:** Implantable devices such as drug-eluting stents and microchips offer sustained release of medications over extended periods. These systems are particularly beneficial for chronic conditions requiring long-term therapy, as they eliminate the need for frequent dosing and ensure consistent drug levels in the bloodstream [22].
- ✓ **Transdermal Drug Delivery:** Transdermal drug delivery systems utilize the skin as a route of administration, bypassing the GIT and hepatic metabolism. Transdermal patches As well as gels provide controlled release of medicament, which offers advantages such as improvement in patient compliance, reduction in systemic side effects, and avoidance of first-pass metabolism [23].
- ✓ **Gene Delivery Systems:** Gene therapy holds immense potential for treating genetic disorders and certain types of cancer. Gene delivery systems such as viral vectors and lipid nanoparticles facilitate the transfer of therapeutic genes into the target cells, which enables the correction of genetic abnormalities or the expression of therapeutic proteins [24.]

NANOTECHNOLOGY-BASED DELIVERY SYSTEMS

Nanotechnology involves the manipulation of the materials and devices at the nanometer scale, having range from 1 to 100 nanometers. At this scale, materials exhibit unique physical, chemical, and biological properties, which can be leveraged for various biomedical applications, including drug delivery. Nanoparticles, nanocarriers, and nanostructured materials serve as the building blocks for nanotechnology-based drug delivery systems, providing advantages such as high surface area-to-volume ratio, tunable surface properties, and precise targeting capabilities [25].

Nanoparticles: Tiny Vehicles with Big Potential

Nanoparticles, colloidal particles typically ranging in size from 1 to 100 nanometers, serve as versatile carriers for therapeutic agents. These nanoparticles can be engineered from a variety of materials, including polymers, lipids, metals, and inorganic substances. By encapsulating drugs within nanoparticles, researchers can achieve controlled release kinetics, protect drugs from degradation, and enhance their bioavailability. Additionally, nanoparticles can be functionalized with the targeting ligands, which allows for precise delivery to specific cells or tissues while minimizing off-target effects [25].

Liposomes: Mimicking Nature for Enhanced Delivery

Liposomes are spherical vesicles which are composed of lipid bilayers, represent a prominent nanotechnology platform for drug delivery. These lipid-based carriers can be used for encapsulation of both hydrophobic as well as hydrophilic drugs within their aqueous core or lipid bilayers, offering versatility in drug loading. Liposomes exhibit prolonged circulation time, improved stability, and enhanced cellular uptake, making them an ideal candidate for delivering a wide range of therapeutics, including anticancer drugs, antibiotics, and vaccines [26].

Polymeric Nanoparticles: Customizing Delivery for Optimal Results

Polymeric nanoparticles, synthesized from biocompatible polymers like poly(lactic-co-glycolic acid) or polyethylene glycol, offer customizable drug delivery platforms with tunable properties. These nanoparticles can be engineered for drug release in a sustained manner, responding to environmental stimuli such as pH, temperature, or enzymatic activity. Polymeric nanoparticles also enable targeted delivery through surface modification with ligands that recognize specific receptors or biomarkers expressed on diseased cells, thus minimizing systemic toxicity and maximizing therapeutic efficacy [25].

Clinical Applications and Future Prospects

Nanotechnology-based drug delivery systems have demonstrated promising applications across a spectrum of therapeutic areas, including oncology, infectious diseases, neurology, and inflammatory disorders. Several nanoparticle-based formulations have progressed to clinical trials and commercialization, underscoring their clinical relevance and translational potential. Moreover, ongoing research endeavors focus on advancing nanotechnology platforms by integrating multifunctional nanoparticles, theranostic agents, and stimuli-responsive delivery systems. These efforts aim to address current challenges in drug delivery, such as overcoming biological barriers, enhancing tissue penetration, and optimizing drug release kinetics [26,27].

POLYMERIC MICELLES

In the pursuit of improving drug delivery systems, scientists have turned to polymeric micelles as a promising solution. These nano-sized structures composed of amphiphilic block copolymers have garnered important attention due to their ability to encapsulate hydrophobic drugs, enhance their solubility, and improve their bioavailability [28].

Understanding Polymeric Micelles

Polymeric micelles are self-assembling nanostructures formed by amphiphilic block copolymers, typically consisting of hydrophilic and hydrophobic segments. In an aqueous environment, these block copolymers spontaneously arrange themselves into micellar structures, with the hydrophobic segments forming the core and the hydrophilic segments forming the corona. This unique architecture allows polymeric micelles to encapsulate hydrophobic drugs within their core while presenting a hydrophilic shell, imparting stability and biocompatibility [29].

Advantages of Polymeric Micelles [28,29]

- **Enhanced Solubility:** Polymeric micelles solubilize hydrophobic drugs by encapsulating them within their core, thus improving their aqueous solubility and bioavailability.
- **Selective Targeting:** The surface of polymeric micelles can be modified with targeting ligands, enabling selective delivery to specific tissues or cells, finally minimizing off-target effects and maximization of therapeutic efficacy.
- **Controlled Release:** Polymeric micelles offer controlled release kinetics, allowing for sustained drug release over an extended period, which can lead to reduced dosing frequency and improved patient compliance.
- **Biocompatibility:** Polymeric micelles are typically composed of biocompatible materials, such as polyethylene glycol and poly(lactic-co-glycolic acid) minimizing the risk of immunogenicity and toxicity.

Applications of Polymeric Micelles

Polymeric micelles have found applications across various therapeutic areas, including oncology, infectious diseases, inflammatory disorders, and cardiovascular diseases [30]. In oncology, polymeric micelles have been extensively investigated for the delivery of chemotherapeutic agents, such as paclitaxel and doxorubicin, enabling targeted delivery to tumor tissues and reducing systemic toxicity. Additionally, polymeric micelles have shown promise in delivering poorly water-soluble drugs, such as curcumin and resveratrol, for the treatment of inflammatory conditions and neurodegenerative diseases [31].

Future Perspectives

The field of polymeric micelles continues to evolve rapidly, with ongoing research focusing on enhancing their capabilities and addressing current challenges. Future efforts aim to develop multifunctional polymeric micelles capable of co-delivering multiple drugs or combining drug delivery with diagnostic imaging modalities, thereby enabling theranostic applications. Moreover, advancements in polymer chemistry and nanotechnology hold promise for the design of stimuli-responsive polymeric micelles that can selectively release drugs in response to specific environmental cues, such as temperature, pH or enzymatic activity. These innovations are poised to drive the development of next-generation drug delivery systems with enhanced precision, efficacy, and patient outcomes [32].

IMPLANTABLE DRUG DELIVERY SYSTEMS

In the realm of modern medicine, the development of implantable DDS represents a remarkable advancement in drug delivery technology. These innovative systems offer targeted and sustained release of therapeutic agents, providing a novel approach to managing various diseases and improving patient outcomes. In this article, we explore the intricacies of implantable drug delivery systems, their applications, advantages, challenges, and future prospects.

UNDERSTANDING IMPLANTABLE DRUG DELIVERY SYSTEMS

Implantable DDS are medical devices designed to administer therapeutic agents directly into the body over an extended period. These systems typically consist of a drug reservoir or matrix enclosed within a biocompatible casing, which is implanted into the patient's body via surgical intervention. The drug release from the implant can be controlled by various mechanisms, including diffusion, osmosis, or mechanical activation [33].

APPLICATIONS OF IMPLANTABLE DRUG DELIVERY SYSTEMS [33,34]

Implantable DDS have found applications across a wide range of therapeutic areas, including:

- **Chronic Pain Management:** Implantable pumps delivering analgesic medications, such as opioids or local anaesthetics, directly to the spinal cord or peripheral nerves can provide long-term pain relief for patients that suffers from chronic pain conditions, like cancer-related pain or neuropathic pain.
- **Hormone Replacement Therapy:** Implantable devices delivering hormones, such as testosterone or estrogen, can be used for hormone replacement therapy in individuals with hormonal imbalances or deficiencies, such as menopausal women or hypogonadal men.
- **Diabetes Management:** Implantable insulin pumps can provide continuous subcutaneous infusion of insulin, mimicking the physiological insulin secretion pattern and offering improved glycemic control for patients with diabetes.
- **Neurological Disorders:** Implantable devices delivering neurostimulants, such as deep brain stimulation or spinal cord stimulation, can modulate neural activity and alleviate symptoms in patients with neurological disorders, such as Parkinson's disease or chronic pain syndromes.

Advantages of Implantable Drug Delivery Systems [33]

- **Targeted Delivery:** Implantable DDS enable targeted delivery of therapeutic agents to specific anatomical sites or tissues, minimizing systemic exposure and reducing the risk of systemic side effects.
- **Sustained Release:** Implantable devices offer sustained release of medications over an extended period, ensuring consistent drug levels in the bloodstream and improving patient compliance by eliminating the need for frequent dosing.
- **Minimally Invasive:** Implantation of drug delivery devices is typically performed using minimally invasive surgical techniques, resulting in shorter recovery times, reduced pain, and improved patient satisfaction compared to traditional surgical interventions.
- **Customizable:** Implantable drug delivery systems can be modified to accommodate individual patient needs, including drug dosage, release kinetics, and duration of therapy, providing personalized treatment options for patients with diverse medical conditions.

Challenges and Future Directions

Despite their numerous advantages, implantable drug delivery systems pose several challenges, including the risk of infection, device malfunction, and tissue rejection. Future research efforts aim to address these challenges by developing advanced biomaterials, innovative drug delivery mechanisms, and smart implantable devices capable of real-time monitoring and feedback. Moreover, ongoing advancements in nanotechnology, biotechnology, and microfabrication hold promise for creating next-generation implantable drug delivery systems with enhanced functionality, biocompatibility, and therapeutic efficacy.

TRANSDERMAL DRUG DELIVERY

Transdermal drug delivery offers efficient and convenient alternative to traditional routes of drug administration. By bypassing the GIT and providing controlled release through the skin, transdermal delivery systems have transformed the landscape of pharmacotherapy. This article explores the principles, advantages, challenges, and applications of transdermal drug delivery, shedding light on its significance in modern medicine [34].

Understanding Transdermal Drug Delivery

Transdermal drug delivery involves the administration of therapeutic agents via skin for systemic absorption. The skin, comprising the outermost layer called the stratum corneum, serves as a protective barrier against external threats while also facilitating the permeation of certain molecules. Transdermal delivery systems leverage this unique property of the skin to deliver drugs across the barrier and into the systemic circulation, bypassing the first-pass metabolism associated with oral administration.

Advantages of Transdermal Drug Delivery [34,35]

- **Convenience:** Transdermal patches provide a convenient and non-invasive method of drug administration, rejecting the need for frequent dosing and reducing patient discomfort associated with injections or oral medications.
- **Steady Drug Levels:** Transdermal delivery systems provide controlled release of drugs for an extended period, resulting in consistent plasma concentrations and improved therapeutic efficacy compared to conventional dosing regimens.
- **Reduced Side Effects:** By avoiding the GIT and hepatic metabolism, transdermal drug delivery minimizes the risk of gastrointestinal irritation, drug degradation, and systemic side effects, enhancing patient safety and tolerability.
- **Enhanced Compliance:** Transdermal patches offer a user-friendly approach to medication adherence, as patients can apply the patches themselves and adhere to a prescribed dosing schedule without the need for frequent supervision or intervention.

Challenges and Considerations [36]

Despite its many advantages, transdermal drug delivery poses several challenges, including:

- **Skin Permeation:** The stratum corneum serves as a formidable barrier to drug permeation, limiting the delivery of certain drugs with large molecular sizes or hydrophilic properties. Strategies to enhance skin permeation include the use of penetration enhancers, chemical enhancers, and physical methods such as iontophoresis and microneedle arrays.
- **Drug Compatibility:** Not all drugs are compatible for transdermal delivery due to their physicochemical properties, including molecular weight, lipophilicity, and ionization state. Drug formulation and optimization are crucial to ensure adequate solubility, stability, and permeation across the skin barrier.
- **Adhesion and Irritation:** Transdermal patches must adhere firmly to the skin while minimizing irritation and allergic reactions. Formulation additives, such as adhesives, gelling agents, and skin-friendly excipients, play a crucial role in achieving optimal patch performance and patient comfort.

Applications of Transdermal Drug Delivery [37,38]

Transdermal DDS have found applications across various therapeutic areas, including:

- **Pain Management:** Transdermal patches delivering analgesic medications, like opioids or NSAIDs, offer effective pain relief for conditions such as chronic pain, arthritis, and postoperative pain.
- **Hormone Replacement Therapy:** Transdermal patches delivering hormones, such as estrogen or testosterone, provide a convenient and continuous delivery system for hormone replacement therapy in menopausal women or individuals with hormonal deficiencies.
- **Nicotine Replacement Therapy:** Transdermal nicotine patches aid in smoking cessation by delivering nicotine gradually, reducing withdrawal symptoms and cravings associated with tobacco addiction.
- **Cardiovascular Disorders:** Transdermal patches delivering cardiovascular medications, such as nitroglycerin or clonidine, offer sustained release and systemic absorption, providing long-term management of hypertension, angina, and heart failure.

FUTURE PERSPECTIVES

The field of transdermal drug delivery continues to evolve with advancements in formulation science, skin permeation enhancers, and novel delivery technologies. Future research aims to overcome current challenges and expand the applicability of transdermal delivery systems to a wider range of drugs and therapeutic indications. Emerging trends include the development of wearable drug delivery devices, smart patches with integrated sensors for real-time monitoring, and personalized transdermal therapies tailored to individual patient needs.

Gene Delivery Systems

In the rapidly evolving landscape of modern medicine, gene delivery systems have emerged as a revolutionary approach to treating a wide range of diseases at their genetic roots. These sophisticated systems facilitate the transfer of therapeutic genes into target cells, offering the promise of personalized, precise, and potentially curative treatments. In this article, we delve into the intricacies of gene delivery systems, exploring their mechanisms, applications, challenges, and promising future prospects [37].

Understanding Gene Delivery Systems

Gene delivery systems encompass a wide range array of technologies which are designed to transport therapeutic genes into target cells, where they can either correct genetic abnormalities or modulate cellular functions [38]. These systems typically consist of vectors, carriers, or nanoparticles that protect and deliver the therapeutic genes to the desired location within the body. Gene delivery systems can be broadly categorized into viral vectors and non-viral vectors, each with its own advantages and limitations.

Viral Vectors: Harnessing Nature's Efficiency

Viral vectors, derived from naturally occurring viruses, are highly efficient at delivering genes into target cells due to their evolved mechanisms of cellular entry and gene expression. Common viral vectors include adenoviruses, lentiviruses, retroviruses and adeno-associated viruses (AAVs) [49,50]. These vectors then are engineered to remove their pathogenic properties while retaining their ability to efficiently deliver therapeutic genes. Viral vectors offer high transduction efficiency and long-lasting gene expression, making them valuable tools for gene therapy applications [38].

Non-Viral Vectors: Engineering Versatility

Non-viral vectors encompass a diverse range of synthetic or naturally occurring carriers, such as liposomes, polymers, nanoparticles, and peptides. Unlike viral vectors, non-viral vectors do not rely on viral components for gene delivery, making them safer and potentially more suitable for clinical use. Non-viral vectors offer advantages such as ease of production, low immunogenicity, and the ability to accommodate large DNA payloads. However, they often exhibit lower transfection efficiency compared to viral vectors and may require optimization for specific applications [38].

Applications of Gene Delivery Systems

Gene delivery systems hold promise for treating a wide range of diseases, which includes genetic disorders, cancer and cardiovascular diseases, neurological disorders, and infectious diseases [39]. In the realm of genetic disorders, gene therapy approaches aim to replace defective or missing genes with functional ones, offering potential cures for conditions such as cystic fibrosis, muscular dystrophy, and hemophilia. In cancer therapy, gene delivery systems can be used to deliver therapeutic genes encoding tumor-suppressive proteins, immunomodulatory factors, or suicide genes directly to cancer cells, thereby inhibiting tumor growth and enhancing the efficacy of conventional treatments [39].

Challenges and Future Directions

Despite the promise of gene delivery systems, several challenges remain to be addressed, including safety concerns, immune responses, off-target effects, and scalability for clinical translation. Ongoing research efforts focus on developing safer and more efficient gene delivery vectors, optimizing delivery strategies, and improving our understanding of the underlying biology of gene therapy. Additionally, advancements in genome editing technologies, such as CRISPR-Cas9, offer exciting opportunities for precise gene editing and targeted therapeutics [40].

IDEAL FEATURES OF NOVEL DRUG DELIVERY SYSTEM

In the realm of pharmaceuticals, the development of NDDS has revolutionized the way drugs are administered and absorbed by the human body. The quest for more effective, targeted, and patient-friendly drug delivery has led researchers and pharmaceutical companies to explore innovative approaches. An ideal drug delivery system is not only about delivering the therapeutic agent but also ensuring optimal therapeutic outcomes while minimizing side effects and enhancing patient compliance. Let's delve into the essential features that define an ideal NDDS.

- **Targeted Delivery:** Precise delivery of drugs to the specific site of action remains a paramount goal. Targeted drug delivery systems ensure that therapeutic agents are directed specifically to the intended site, minimizing off-target effects and maximizing efficacy [40].
- **Controlled Release:** Sustained as well as controlled release of drugs over an extended period is crucial for maintaining therapeutic concentrations within the body. Controlled-release systems offer advantages like reduced dosing frequency, improved patient compliance, and minimized fluctuations in drug levels [40].
- **Biocompatibility:** Compatibility with biological systems is imperative to prevent adverse reactions or immune responses. Ideal drug delivery systems should be biocompatible, ensuring they interact safely with the body's tissues and fluids without eliciting harmful effects [40].
- **Biodegradability:** Biodegradable NDDS are designed to degrade or metabolize within the body, eliminating the need for removal surgeries or interventions. Biodegradability enhances safety and reduces the risk of long-term accumulation of foreign materials in tissues [40].
- **Enhanced Stability:** Maintaining the stability of drugs during storage and administration is critical for preserving their therapeutic efficacy. Novel delivery systems should protect drugs

from degradation due to environmental factors, ensuring their stability until they reach the target site [40].

- **Reduced Side Effects:** Minimizing adverse effects associated with drug therapy is a primary objective of NDDS. By targeting drugs specifically to diseased tissues and avoiding exposure to healthy tissues, these systems can mitigate side effects and improve patient tolerability [41].
- **Ease of Administration:** Patient compliance greatly influences the success of drug therapy. Ideal delivery systems should be convenient and easy to administer, whether through oral, transdermal, inhalation, or other routes, to enhance patient acceptance and adherence to treatment regimens [42].
- **Versatility:** Flexibility in design and application allows NDDS to accommodate a wide number of drugs with varying properties. Versatile delivery systems can encapsulate diverse drug molecules, including small molecules, biologics, and nucleic acids, expanding their utility across therapeutic areas [43].
- **Scalability:** Scalability is essential for the translation of novel delivery systems from research to commercial production. Systems that can be manufactured reliably and cost-effectively on a large scale are crucial for widespread accessibility and affordability of advanced therapies [43].
- **Non-Invasive Routes:** Non-invasive delivery routes, such as oral, nasal, or transdermal administration, offer advantages in terms of patient comfort, convenience, and safety. NDDS designed for non-invasive routes provide alternatives to traditional injection-based therapies, enhancing patient acceptance and adherence [44].

In conclusion, the ideal features of novel drug delivery systems encompass targeted delivery, controlled release, biocompatibility, biodegradability, stability, reduced side effects, ease of administration, versatility, scalability, and non-invasive routes. Achieving these features requires interdisciplinary collaboration among scientists, engineers, and clinicians to innovate and refine drug delivery technologies. As research continues to advance, the realization of ideal drug delivery systems holds the promise of revolutionizing patient care and improving therapeutic outcomes across a spectrum of diseases.

MERITS AND DEMERITS OF NDDS

Merits of NDDS

- **Enhanced Targeting:** One of the primary merits of NDDS is their ability to precisely target specific tissues, cells, or organs within the body. Through advanced formulations and targeting ligands, these systems can deliver drugs directly to the specific site of action, maximizing therapeutic efficacy while minimizing off-target effects [45].
- **Improved Pharmacokinetics:** Novel drug delivery systems offer superior control over drug release kinetics, resulting in optimized pharmacokinetic profiles. By sustaining drug levels within the therapeutic window for extended durations, these systems enhance drug efficacy and minimize fluctuations in plasma concentrations, leading to improvement in therapeutic outcomes [45].
- **Reduced Side Effects:** Conventional drug formulations often pose challenges in terms of systemic toxicity and adverse effects on healthy tissues. NDDS mitigate these concerns by enabling targeted delivery and controlled release, thereby minimizing off-target interactions and reducing the risk of side effects. This enhances patient safety and tolerability of pharmacotherapy [46].
- **Enhanced Bioavailability:** Poor bioavailability is a common limitation associated with many drugs, stemming from factors such as low solubility, poor permeability, and extensive first-pass metabolism. Novel drug delivery systems employ strategies such as encapsulation, nanosizing, and formulation optimization to enhance drug solubility, permeability, and bioavailability, ensuring more efficient drug delivery and improved therapeutic efficacy [47].
- **Tailored Release Profiles:** Customized release profiles are essential for optimizing drug therapy and achieving desired therapeutic outcomes. NDDS offer the flexibility to design release profiles tailored to the pharmacokinetic and pharmacodynamic requirements of specific drugs and disease conditions. This allows for personalized treatment regimens and improved patient response to therapy [47].
- **Versatility and Adaptability:** Novel drug delivery systems encompass a wide range of platforms and technologies, including liposomes, nanoparticles, micelles, hydrogels, and implants, among others. This versatility allows for the delivery of diverse drug molecules, including small

molecules, biologics, and nucleic acids, across various routes of administration, offering solutions for a broad spectrum of therapeutic challenges [48].

- **Prolonged Durations of Action:** Extended-release formulations are particularly valuable in chronic conditions where sustained therapeutic effects are desired over prolonged periods. NDDS enable the development of formulations with prolonged durations of action, reducing dosing frequency and improving patient compliance. This not only enhances convenience but also optimizes therapeutic outcomes [49].
- **Non-Invasive Administration Routes:** Non-invasive RoA, such as oral, transdermal, and nasal delivery, offer advantages in terms of patient comfort, convenience, and compliance. Novel drug delivery systems designed for non-invasive routes enhance patient acceptance and adherence to therapy, contributing to improved treatment outcomes and overall patient satisfaction [58].
- **Combination Therapies:** The ability to co-deliver multiple drugs or therapeutic agents within a single delivery system offers significant advantages in the treatment of complex diseases and multifactorial conditions. NDDS facilitate combination therapies by providing controlled release of multiple agents, optimizing synergistic effects, and minimizing drug interactions, thereby enhancing therapeutic efficacy and simplifying treatment regimens [59].
- **Translation to Clinical Practice:** The merits of novel drug delivery systems extend beyond the laboratory to real-world clinical practice. Many NDDS have successfully transitioned from preclinical development to clinical trials and commercialization, demonstrating their feasibility, safety, and efficacy in diverse patient populations. This translational success underscores the transformative potential of NDDS in modern medicine [60].

Demerits of NDDS

Novel drug delivery systems (NDDS) have revolutionized the field of pharmaceuticals by offering numerous advantages, they are not without their limitations and drawbacks. Despite their potential to improve therapeutic outcomes and patient compliance, certain demerits exist that warrant consideration. In this article, we delve into some of the demerits associated with novel drug delivery systems[61].

- **Complex Formulation Development:** The design and development of novel drug delivery systems often involve intricate formulation processes, requiring specialized expertise and resources. Complex formulations can increase production costs, prolong development timelines, and pose challenges in scaling up manufacturing processes, limiting their widespread adoption. [62]
- **Potential Biocompatibility Issues:** While biocompatibility is a key consideration in the design of NDDS, there is always a risk of adverse reactions or immune responses. The introduction of foreign materials or excipients in delivery systems may trigger inflammatory reactions or hypersensitivity responses in some individuals, compromising patient safety and tolerability. [63]
- **Limited Stability:** Some novel drug delivery systems may exhibit limited stability under certain conditions, leading to degradation or loss of efficacy over time. Factors such as exposure to light, temperature fluctuations, or interactions with biological fluids can compromise the stability of formulations, affecting their shelf life and therapeutic performance. [64]
- **Potential Toxicity Concerns:** Certain components or materials used in NDDS, such as nanoparticles or polymers, may raise concerns regarding their long-term safety and potential toxicity. While extensive preclinical testing is conducted to evaluate the biocompatibility and safety profile of these systems, the long-term effects of their exposure in vivo may not always be fully understood. [65]
- **Risk of Unintended Side Effects:** Despite efforts to minimize off-target effects, novel drug delivery systems may still pose risks of unintended side effects. Factors such as non-specific accumulation in tissues, incomplete biodegradation, or unintended interactions with biological molecules may lead to adverse effects that were not anticipated during the formulation design phase. [66]
- **Challenges in Regulatory Approval:** The regulatory approval process for novel drug delivery systems can be rigorous and time-consuming. Regulatory agencies require comprehensive data on the safety, efficacy, and quality of NDDS, including preclinical and clinical studies, to assess their suitability for commercialization. Delays in regulatory approval can hinder market access and limit patient access to innovative therapies. [67]
- **Cost Considerations:** The development and production of novel drug delivery systems may entail higher costs compared to conventional drug formulations. Sophisticated technologies,

specialized equipment, and quality control measures contribute to increased manufacturing expenses, potentially resulting in higher drug prices. Accessibility and affordability of NDDS may thus pose challenges, particularly in resource-limited settings. [68]

- **Complexity in Administration:** Some novel drug delivery systems may require specialized administration techniques or equipment, increasing the complexity of drug administration. This can pose challenges in healthcare settings where healthcare providers may lack the necessary training or resources to administer these formulations properly. Complexity in administration may also impact patient adherence to treatment regimens. [69]
- **Risk of Technical Challenges:** The implementation of novel drug delivery systems in clinical practice may encounter technical challenges related to device functionality, compatibility with existing healthcare infrastructure, and user acceptance. Technical issues such as device malfunction, inadequate training, or improper handling may compromise the effectiveness and reliability of NDDS, affecting patient outcomes. [67]
- **Limited Clinical Evidence:** Despite promising preclinical data, the clinical evidence supporting the efficacy and safety of some novel drug delivery systems may be limited. Clinical trials involving NDDS may face challenges such as small sample sizes, variability in patient populations, or insufficient follow-up duration, leading to uncertainties regarding their real-world effectiveness and long-term outcomes. [65]

FUTURE PROSPECTS OF NDDS

In the ever-evolving landscape of pharmaceuticals, the future holds immense promise for novel drug delivery systems (NDDS) to revolutionize the way drugs are administered, absorbed, and utilized within the human body. With advances in materials science, nanotechnology, biotechnology, and computational modeling, researchers are poised to unlock new frontiers in drug delivery, offering unprecedented precision, efficacy, and patient-centric approaches. In this article, we explore the exciting future prospects of NDDS and their potential to shape the future of medicine[70].

- **Personalized Medicine:** One of the most anticipated prospects of NDDS is the realization of customized medicine. By tailoring drug delivery systems to individual patient characteristics, including genetic makeup, physiological parameters, and disease profiles, healthcare providers can optimize treatment outcomes while minimizing adverse effects. Personalized NDDS hold the promise of delivering the right drug, at the right dose, to the correct patient, at the right time, ushering in a new era of precision medicine.
- **Targeted Therapy:** The future of drug delivery lies in increasingly precise targeting strategies. Advanced targeting ligands, such as antibodies, peptides, and aptamers, coupled with innovative delivery platforms, enable NDDS to selectively hone in on diseased tissues, cells, or even intracellular targets. Targeted therapy not only enhances therapeutic efficacy but also minimizes off-target effects, thereby improving patient safety and tolerability. [71]
- **Smart Drug Delivery Systems:** The integration of smart technologies into drug delivery systems heralds a paradigm shift in healthcare. Smart NDDS equipped with sensors, actuators, and feedback mechanisms can respond dynamically to physiological cues, enabling real-time adjustments in drug release rates, dosing schedules, and therapeutic interventions. These intelligent systems hold immense potential for enhancing treatment outcomes, optimizing drug regimens, and improving patient adherence. [72]
- **Biomimetic Delivery Platforms:** Nature serves as a rich source of inspiration for the design of biomimetic drug delivery systems. By mimicking biological structures, processes, and mechanisms, biomimetic NDDS offer enhanced biocompatibility, targeted delivery, and controlled release properties. From synthetic vesicles inspired by cell membranes to nanoparticles modeled after viral vectors, biomimetic delivery platforms hold promise for overcoming biological barriers and optimizing therapeutic delivery. [73]
- **Gene and Cell Therapies:** The advent of gene editing technologies and cell-based therapies has opened new frontiers in the treatment of genetic disorders, cancers, and regenerative medicine. NDDS play an important role in facilitating the delivery of nucleic acids, gene editing tools, and therapeutic cells to target tissues or organs. Engineered delivery systems are capable of traversing biological barriers, evading immune surveillance, and achieving sustained transgene expression hold immense potential for advancing gene and cell therapies. [74]
- **Combination Therapies:** The future of drug delivery lies in the synergistic integration of multiple therapeutic modalities within a single delivery system. Combination therapies, which

combine drugs, biologics, nucleic acids, or imaging agents, offer enhanced efficacy, reduced drug resistance, and improved treatment outcomes. NDDS capable of co-delivering multiple agents with spatial and temporal precision hold promise for tackling complex diseases and overcoming therapeutic challenges. [75]

- **Bioresponsive Nanomedicines:** Nanotechnology-enabled drug delivery systems are poised to evolve into bioresponsive platforms that dynamically interact with biological systems. By harnessing stimuli-responsive materials, such as pH-sensitive polymers, temperature-responsive hydrogels, or enzyme-triggered nanoparticles, bio-responsive NDDS can modulate drug release in response to specific physiological cues or disease states. These adaptive systems offer precise control over drug delivery kinetics, enhancement in therapeutic efficacy and minimizing side effects. [76]
- **Regenerative Medicine:** NDDS hold transformative potential in the area of regenerative medicine, where the goal is to replace repair, or regenerate damaged tissues or organs. Biomaterial-based scaffolds, growth factor-releasing microspheres, and cell encapsulation systems serve as platforms for delivering therapeutic agents to promote tissue regeneration and wound healing. Advanced NDDS that facilitate the controlled delivery of bioactive molecules, cells, and signaling cues offer new avenues for regenerative therapies.

REFERENCES

1. Rayaprolu BM, Strawser JJ, Anyarambhatla G. (2018). Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. *Drug Dev Ind Pharm.* 44(10):1565-1571.
2. Vargason AM, Anselmo AC, Mitragotri S. (2021). The evolution of commercial drug delivery technologies. *Nat Biomed Eng.* 5(10):951-967.
3. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. (2021). Advances in oral drug delivery. *Front Pharmacol.* ;12:618411.
4. Sahoo D, Bandaru R, Samal SK, Naik R, Kumar P, Kesharwani P, Dandela R. (2021). Oral drug delivery of nanomedicine. In: Kesharwani P, Taurin S, T.-T. KB, Greish NNG (Eds.), *Advances in Nanomedicine*, Academic Press; p. 181-207.
5. Morales JO, Vuddanda PR, Velaga S. (2021). Controlled drug delivery via the buccal and sublingual routes. In: *Fundamentals of Drug Delivery.* p. 433-448.
6. N.R. Hussein, H.K. Omer, A.M.A. Elhissi, W. Ahmed, in: W. Ahmed, D.A. Phoenix, M.J. Jackson, C.P.B.T.-A. in M., S.E. (2020). Charalambous (Eds.), Chapter 15 - Advances in Nasal Drug Delivery Systems, Academic Press pp. 279–311.
7. Chauhan A, Fitzhenry L, Serro AP. (2022). Recent advances in ophthalmic drug delivery. *Ther Deliv*, 1(3):435-56. doi: 10.4155/TDE.10.40. .
8. Thirunavukkarasu A, Nithya R, Jeyanthi J. (2022). Transdermal drug delivery systems for the effective management of type 2 diabetes mellitus: a review. *Diabetes Res Clin Pract.* 109996.
9. Sharma P, Gajula K, Dingari NN, Gupta R, Gopal S, Rai B, Iacocca RG. (2022). Subcutaneous drug delivery: a review of the state-of-the-art modelling and experimental techniques. *J Biomech Eng.* doi: 10.1115/1.4055758.
10. Misbah Ul Haq M, Razzak M, Uddin MA, Ahmed N, Shahidulla D. (2021). Rectal drug delivery system: an overview. *Clin Pharmacol Biopharm.* 10.
11. Mahant S, Sharma AK, Gandhi H, Wadhwa R, Dua K, Kapoor DN. (2022). Emerging trends and potential prospects in vaginal drug delivery. *Curr Drug Deliv.* 20(6):730-751. doi: 10.2174/1567201819666220413131243.
12. Cho M, Joo M, Kim K, Wook Y, Lee S, Mi Y, Ho I. (2018). The immunotherapeutic effects of recombinant Bacillus rin resistant to antimicrobial peptides on Calmette-Guérin bladder cancer cells. *Biochem Biophys Res Commun.* doi: 10.1016/j.bbrc.2018.12.097.
13. Palugan L, Cerea M, Cirilli M, Moutaharrik S, Maroni A, Zema L, Melocchi A, Uboldi M, Filippin I, Foppoli A, Gazzaniga A. (2021). Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. *Int J Pharm X.* 23;3:100100. doi: 10.1016/j.ijpx.2021.100100. PMID: 34765967; PMCID: PMC8569723.
14. B.D. Mattos, O.J. Rojas, W.L.E. Magalh, (2017). Biogenic silica nanoparticles loaded with neem bark extract as green, slow-release biocide ; 142:4206–4213.
15. Charman WN, Chan K, Finnin BC, Charman SA. (1999). Drug delivery: a key factor in realizing the full therapeutic potential of drugs. *Drug Dev Res.* ;46:316-27.
16. Santini JT, Richards AC, Scheidt R, Cima MJ and Langer R. (2000). Microchips as Controlled Drug- Delivery Devices. *Angew. Chem. Int. Ed.* 39: 2396-407.
17. Niculescu-Duvaz I, Springer CJ. (1997). Antibody-directed enzyme prodrug therapy (ADEPT): a review. *Advanced Drug Delivery Reviews;* 26: 151-72.
18. Manabe T, Okino H, Maeyama R, Mizumoto K, Nagai E, Tanaka M, Matsuda T. (2004). Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: transtissue, sustained local drug-delivery systems. *Journal of Controlled Release* 100: 317-30.

19. Ziaie B, Baldi A, Lei M, Gu Y, Siegel RA. (2004). Hard and Soft Micro machining for Biomems. Review of Techniques and Examples of Applications in Microfluidics and Drug Delivery. *Advanced Drug Delivery Reviews* 56: 145-72.
20. Li, S., & Huang, L. (2020). Nanotechnology based drug delivery systems: an introduction. *Nanotechnology Reviews* 9(1):1-14.
21. Talelli, M. et al. (2011). Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. *Nanomedicine* ;6(5):105-117.
22. Zhang, L. et al. (2017). Implantable drug-delivery devices: current status and future perspectives. *Expert Opinion on Drug Delivery*;14(7):1-15.
23. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*;26(11):1261-1268.
24. Wang, Y., & Huang, L. (2019). Recent advancements in nanoparticle-mediated siRNA delivery. *Annual Review of Biomedical Engineering*;21:75-94.
25. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nature Biotechnology* ;33(9):941–951.
26. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery* ;13(11):813–827.
27. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumours. *Nature Reviews Materials*, 1(5): 16014.
28. Talelli, M., Barz, M., Rijcken, C. J., Kiessling, F., & Hennink, W. E. (2011). Polymeric micelles for cancer therapy: 3. Preparation of responsive systems. *Journal of Controlled Release*, 151(3):176-183.
29. Shi, Y., & Lammers, T. (2019). Combining nanomedicine and immunotherapy. *Accounts of Chemical Research*, 52(6):1543-1554.
30. Zhang, Z., Xiong, X., Wan, J., & Wang, A. (2017). Polysaccharides-based nanoparticles as drug delivery systems. *Advanced Drug Delivery Reviews*;105:230-250.
31. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: an overview of biomedical applications. *Journal of Controlled Release* ;161(2):505-522.
32. Medtronic. (2020). Implantable drug delivery systems. Retrieved from <https://www.medtronic.com/us-en/healthcare-professionals/therapies-procedures/drug-delivery/implantable-drug-delivery-systems.html>
33. Colombo, P., Bettini, R., & Peppas, N. A. (2000). Observation of swelling process and drug release in hydrophilic matrix tablets by environmental scanning electron microscopy (ESEM). *Journal of Controlled Release*, 63(1-2), 179-188.
34. Ratner, B. D., & Hoffman, A. S. (1976). Synthetic hydrogels for biomedical applications. *Hydrogels for Medical and Related Applications*, 1-28.
35. Piazza, R., & Bostman, O. (2003). Biodegradable drug delivery systems for fracture fixation. *Clinical Orthopaedics and Related Research*,372, 71-79.
36. Langer, R., & Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. *Nature*, 63(5580);797-800.
37. Peppas, N. A., & Langer, R. (1994). New challenges in biomaterials. *Science*, 263(5154):1715-1720.
38. Hadgraft, J., & Lane, M. E.. (2014). Drug permeation through the skin: a mechanistic view. In *Handbook of Non-Invasive Drug Delivery Systems*; 1-22.
39. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences*, 14(2):101–114.
40. Prausnitz, M. R., & Mitragotri, S. (2004). Transdermal delivery: overcoming the skin's barrier function. *Pharmaceutical Science & Technology Today*, 3(9):318–326.
41. Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. *Advanced Drug Delivery Reviews*, 56(5):603–618.
42. Benson, H. A. E. (2005). Transdermal drug delivery: penetration enhancement techniques. *Current Drug Delivery*, 2(1): 23–33.
43. Yin, H., & Kanasty, R. L. et al. (2014). Non-viral vectors for gene-based therapy. *Nature Reviews Genetics*, 15(8):541-555.
44. Ginn, S. L., & Alexander, I. E. et al. (2018). Gene therapy clinical trials worldwide to 2017: An update. *Journal of Gene Medicine*, 20(5):3015.
45. Hacein-Bey-Abina, S., & Von Kalle, C. et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science*, 302(5644): 415-419.
46. Adair, J. E., & Johnston, S. K. et al. (2018). Gene therapy for hemoglobinopathies. In *Molecular Therapy* ;26(5):1238-124.
47. Ginn, S. L., & Amaya, A. K. et al. (2018). Gene therapy clinical trials worldwide to 2017: An update. *Journal of Gene Medicine*, 20(5):3015.
48. Aiuti, A., & Roncarolo, M. G. et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. *New England Journal of Medicine*, 360(5), 447-458.
49. Maruggi, G., & Porcellini, S. et al. (2019). Current trends in cancer therapy. *Journal of Experimental & Clinical Cancer Research*,38(1):1-18.
50. Wang, Y., & Nakamura, M. et al. (2019). Nanoparticle-mediated delivery of suicide genes in cancer therapy. *Theranostics*, 9(26):7889.

51. Truong, N. P., & Whittaker, M. R. et al. (2015). The importance of nanoparticle shape in cancer drug delivery. *Expert Opinion on Drug Delivery*,12(1):129-142.
52. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. *Advanced drug delivery reviews*, 65(1):36-48.
53. Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999). Polymeric systems for controlled drug release. *Chemical reviews*, 99(11):3181-3198.
54. Torchilin, V. P. (2007). Micellar nanocarriers: pharmaceutical perspectives. *Pharmaceutical research*,24(1):1-16.
55. Langer, R., & Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. *Nature*, 263(5580):797-800.
56. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., ... & Proksch, P. (2008). Prodrugs: design and clinical applications. *Nature reviews Drug discovery*,7(3):255-270.
57. Lee, J., & Lee, S. Y. (2010). Controlled drug delivery systems: beyond immediate release. *Journal of controlled release*, 150(1):1-2.
58. Banik, B. L., & Fattahi, P. (2019). Brownian dynamics simulations of nanoparticles in biological systems. *Journal of nanobiotechnology*, 17(1):1-14.
59. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature nanotechnology*, 2(12):751-760.
60. Prausnitz, M. R., & Langer, R. Transdermal drug delivery. *Nature biotechnology*, 2008;26(11):1261-1268.
61. Lemoine, D., & Francois, C. Polymeric drug delivery systems: a role for formulation in the controlled release of drugs by subcutaneous injection. In *Polymeric Delivery of Therapeutics 2012*;175-199.
62. Jhunjhunwala, S., & Langer, R. (2014). Biocompatible delivery systems for vaccines. *Advanced drug delivery reviews*, 78, 29-42.
63. Li, W., & Huang, Z. Polymeric nanoparticle drug delivery systems: classification, degradation pathways, and degradation products. *Expert opinion on drug delivery*, 2016;13(1):12-14.
64. Zhang, L., & Gu, F. X. (2008). Chan, J. M., Valencia, P. M., & Langer, R. S. Farokhzad, O. C., & Langer, R. (2009). Nanotechnology for drug delivery: the perfect partnership. *Expert opinion on drug delivery*, 2010;6(3):297-307.
65. Hillaireau, H., & Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. *Cellular and molecular life sciences*, 2009;66(17):2873-2896.
66. Verma, S., & Kumar, M. (2011). Recent advances in novel drug delivery systems. *Pharmaceutical research*, 28(7):1167-1168.
67. Babu, A., & Templeton, A. C. (2011). Nanotechnology platforms and physiological challenges for cancer therapeutics. *Nanomedicine: Nanotechnology, Biology and Medicine*, 7(2):122-123.
68. Langer, R., & Peppas, N.. (1981). Present and future applications of biomaterials in controlled drug delivery systems. *Biomaterials*, 2(4):201-214.
69. Farokhzad, O. C., & Langer, R. Impact of nanotechnology on drug delivery. *ACS nano*, 2009;3(1):16-20.
70. Garikipati, K. Personalized Medicine: An Overview of Targeted Drug Delivery Systems. *Journal of Pharmacology and Pharmacotherapeutics*, 2020;11(2):41-48.
71. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C.. Analysis of nanoparticle delivery to tumours. *Nature Reviews Materials*, 2016;1(5): 16014.
72. Veisoh, O., & Langer, R. Smart polymers for controlled drug delivery. *Drug Delivery and Translational Research*, 2015;5(6):511-512.
73. Discher, D. E., & Eisenberg, A.. (2002). Polymer vesicles. *Science*.297(5583):967-973.
74. Zhang, Y. N., & Gu, W. (2016). Polymeric Nanoparticles: Engineering Strategies and Recent Advances. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 9(3):1409.
75. Lv, Q., & Yu, A. (2018). Stimuli-responsive nanomaterials for therapeutic protein delivery. *Journal of Materials Chemistry B*, 6(22):3574-3585.
76. Lim, K. S., & Lee, Y. M.. (2014). Advanced Biomaterials for Regenerative Medicine and Drug Delivery. *Journal of Tissue Engineering*, 5:1-25.

<p>Copyright: © 2025 Author. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
--